Cassava Sciences: From Alzheimer’s Drug Game-Changer to an 83% Stock Plunge

Hey everyone, any $SAVA investors here? If you missed it, I shared some Cassava Sciences info a few weeks ago, but since the deadline is this week, I thought it worth sharing it again.  If you’ve been following Cassava Sciences, you know their Alzheimer’s drug Simufilam was a big story in 2024—and not in a good way. So, here’s a recap of what happened and the latest updates on the investor lawsuit. Earlier last year, [Cassava Sciences touted promising Phase 2 results for Simufilam](https://www.biospace.com/no-decline-in-cognition-scores-in-patients-with-mild-alzheimer-s-disease-who-received-simufilam-continuously-for-24-months), claiming it could prevent cognitive decline in mild Alzheimer’s patients over two years. The company presented the drug as a potential "disease-modifying treatment" and even began preparing for its commercial launch. But on November 25, 2024, [Cassava announced that Simufilam had failed to meet any goals ](https://www.science.org/content/article/damning-fda-inspection-report-undermines-positive-trial-results-possible-alzheimer-s)in its Phase 3 ReThink-ALZ trial. None of the primary, secondary, or exploratory endpoints were achieved. https://preview.redd.it/fcj73jpiakhe1.png?width=1532&format=png&auto=webp&s=c091641cdf08adb965c28e4933d4eb73feb78893 The fallout was immediate: $SAVA shares plummeted by 83.76%. To make matters worse, Cassava canceled other Phase 3 trials and terminated open-label extension studies for Simufilam, effectively ending its development. At this point, investors filed a lawsuit against Cassava, accusing the company of overstating the drug’s potential while downplaying significant limitations in its data and development process. So, for all affected— you can [check the details here](https://11thestate.com/cases/cassavaascience-investor-suit), and if you have anything to say about your damages / more info, you’re very welcome to share it here.